Pharmaceutical market research · Mexico and LATAM

Evidence before the decision.

We design the study, run fieldwork on our own physician panel and model the result until it answers your business question. Declared method, declared sample, findings with the decision attached.

Request a proposal See the seven methodologies

Scope, method and investment range in under 48 business hours.

1,000+: Physicians with validated license and active practice in our own panel; active roster · Jan 2026
15+: Medical specialties with in-house field coverage; oncology to internal medicine
32: States covered, public sector and private institutional; IMSS · ISSSTE · IMSS-Bienestar · private
15 years: Of team experience with global Top 10 pharmaceutical companies; results under NDA

01 · Portfolio

Seven methodologies, each with a declared purpose

They are chosen by the decision in front of you, not from a catalogue. They almost always combine: one maps the terrain, another keeps it measured over time.

Compare the seven methodologies

Each page declares minimum sample, field timing, deliverable and the function it answers to.

02 · Methodological rigor

The method is declared before fieldwork begins

Every study ships with its protocol: what was asked, of whom, how the sample was selected and the margin of error each figure carries. Without that, a finding is an expensive opinion.

Phase 01
Design

We translate the business question into measurable hypotheses and define universe, sampling frame, inclusion criteria and statistical power. The protocol is signed before recruitment starts.
Phase 02
Field

Recruitment from our own panel with professional license and active practice verification. Double quality control: validation at capture and audit of 20% of interviews. We also field on the client's own panel, according to the needs and definitions of the study.
Phase 03
Analysis

Weighting to the physician universe, declared significance testing and 95% confidence intervals. Every table travels with its base and its error level.
Phase 04
Decision

The report closes with the action: what to do, in what priority, what gets re-measured and when. Working session with your team included.

Standards we apply

ISPOR for cost-effectiveness, cost-utility and budget impact models.
PRISMA for the systematic review feeding the epidemiological models.
LFPDPPP and informed consent for every personal data point collected in the field.
Pharmacovigilance: reporting protocol for adverse events detected during interviews.

03 · Who we answer to

Three functions, three different questions

Brand marketing

The physician receives five competing messages a week and the patient rarely arrives adherent. That is where your share is decided, and that is where we measure.

Market Access

IMSS, ISSSTE, IMSS-Bienestar and PEMEX do not buy without evidence of economic value. We build the quantitative argument that withstands review.

Medical Affairs

There is a gap between trial evidence and Mexican clinical practice. We measure it: real-world use, referral patterns and guideline adherence.

04 · Proprietary panel

Verified specialists, not rented panels

Data quality starts with who answers. We recruit and validate every physician: professional license, specialty, institution and real consultation volume. No one joins the panel without documentary verification.

That enables something a rented panel cannot: reaching exactly the same cohort wave after wave and reading the change instead of the noise.

How the panel is built

Validated professional license100% of the roster
Verified active clinical practicesemi-annual review
Public, institutional and private coverageIMSS · ISSSTE · IMSS-Bienestar · private
Stable cohort for longitudinal studiesretention > 80% per wave
Typical field time3–6 weeks
Specialties with sufficient base15+ · n ≥ 60 each

05 · Case studies

Studies that changed a decision

Projects anonymised under confidentiality agreement. We publish the challenge, the methodology and the decision the study enabled; quantitative results remain the client's property.

Oncology · NSCLC

Time to confirmed diagnosis

The Patient Journey isolated a referral barrier between pulmonology and oncology. Redesigning the message to first-contact physicians shortened the patient route.

Patient Journey

Diabetes · GLP-1

Porcentaje de uso

Four Brand Tracker waves caught the competitor's narrative shift a quarter before the planning cycle. The brand reacted in time.

Brand Tracker

Biologic · Access

Inclusion in institutional formulary

The pharmacoeconomic dossier withstood review and secured inclusion in the first evaluation cycle, with no round of clarifications.

Pharmacoeconomics / HEOR · ISPOR standard

See all case studies

Tell us what you need to measure.

In under 48 business hours you receive scope, methodology, proposed sample, field timing and investment range. No cost, no commitment.

Request a proposal

hola@scopusconsulting.com.mx
442 194 7770 · Mon–Fri 9:00–19:00 CT

Evidence before the decision.

Seven methodologies, each with a declared purpose

Targeting

Patient Journey

Usage & Attitudes

Brand Tracker

Epidemiological models

Pharmacoeconomics / HEOR

Ad hoc research